News Agency
The Times

Ractigen Therapeutics Receives IND Approval from China's NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients

  • Written by PR Newswire

SUZHOU, China, May 15, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing pioneering therapies, today announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for the...

Read more: Ractigen Therapeutics Receives IND Approval from China's NMPA to Initiate Phase 1 Clinical Trials...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion